MAVALON THERAPEUTICS
Mavalon Therapeutics is a company focused on stopping the progression of Parkinson’s disease. The biotechnology company is developing mGluR3 allosteric modulators for the treatment of Parkinson's disease.
MAVALON THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Hatfield, Hertford, United Kingdom
Country:
United Kingdom
Total Employee:
1+
Status:
Active
Total Funding:
9 M EUR
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Vincere Biosciences
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD).
Investors List
Domain Therapeutics
Domain Therapeutics investment in Seed Round - Mavalon Therapeutics
Medicxi
Medicxi investment in Seed Round - Mavalon Therapeutics
More informations about "Mavalon Therapeutics"
Mavalon Therapeutics - Crunchbase Company Profile & Funding
Mavalon Therapeutics is a company focused on stopping the progression of Parkinson’s disease. The biotechnology company is developing mGluR3 allosteric modulators for the treatment of …See details»
Mavalon Therapeutics Company Profile 2024: Valuation, Funding ...
Developer of an oral drug intended to treat Parkinson's disease (PD). The company's drugs halt the progression of the disease and aims to stop and reverse the effects, enabling physicians to …See details»
Domain Therapeutics and Medicxi launch Mavalon Therapeutics, …
Oct 18, 2016 · Newly formed Mavalon Therapeutics is developing the first orally available small molecule able to induce GDNF production within the brain of Parkinson’s patients, a treatment …See details»
Domain Therapeutics 161018 Mavalon EN
Newly formed Mavalon Therapeutics is developing the first orally available small molecule able to induce GDNF production within the brain of Parkinson’s patients, a treatment that will bring …See details»
Canada’s Domain Therapeutics creates new company to stop …
Oct 20, 2016 · The newly formed company Mavalon Therapeutics is developing the first orally available small molecule able to induce GDNF production within the brain of patients with …See details»
Mavalon Therapeutics - Funding, Financials, Valuation & Investors
Mavalon Therapeutics is funded by 2 investors. Domain Therapeutics and Medicxi are the most recent investors.See details»
Domain Therapeutics and Medicxi launch Mavalon Therapeutics, …
Nov 7, 2016 · Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein-coupled receptor (GPCR) drugs, today announces …See details»
Canada’s Domain Therapeutics creates new company to stop …
Oct 20, 2016 · Canada’s Domain Therapeutics has created new company Mavalon Therapeutics to halt the progression of Parkinson’s disease.See details»
Mavalon Therapeutics Ltd - Company Profile and News
Company profile page for Mavalon Therapeutics Ltd including stock price, company news, executives, board members, and contact informationSee details»
Domain Therapeutics and Medicxi launch Mavalon Therapeutics
Oct 19, 2016 · Medicxi will invest up to €9m ($10m) in the asset-centric company to show clinical efficacy of Mavalon's GDNF-inducer drug candidate, an mGluR3 PAM molecule discovered by …See details»
Mavalon Therapeutics - Products, Competitors, Financials, …
Domain Therapeutics, a biopharmaceutical company that specializes in the discovery and development of G protein -coupled receptor (GPCR) drugs, today announces the creation of …See details»
Mavalon Therapeutics - VentureRadar
We target signaling proteins based on emerging biological concepts and discover novel mechanisms for modulating these targets with small molecule drugs. Our leadership team has …See details»
Domain Therapeutics And Medicxi Launch Mavalon Therapeutics …
Oct 18, 2016 · Newly formed Mavalon Therapeutics is developing the first orally available small molecule able to induce GDNF production within the brain of Parkinson’s patients, a treatment …See details»
Medicxi founds Parkinson’s startup, commits €9M
Oct 18, 2016 · Mavalon Therapeutics, the asset-centric company founded to advance the candidate, will receive up to €9 million ($10 million) from Medicxi.See details»
Mavalon Therapeutics - Updates, News, Events, Signals & Triggers
Oct 18, 2016 · Mavalon is developing drugs to stop the progression of Parkinson's disease.See details»
Domain Therapeutics and Medicxi launch Mavalon Therapeutics, …
Oct 18, 2016 · Newly formed Mavalon Therapeutics is developing the first orally available small molecule able to induce GDNF production within the brain of Parkinson’s patients, a treatment …See details»
Mavalon Therapeutics - Tech Stack, Apps, Patents & Trademarks
Mavalon is developing drugs to stop the progression of Parkinson's disease.See details»
Mavalon Therapeutics Ltd. | Insights
Nov 11, 2016 · Mavalon Therapeutics Ltd. Industry. Pharmaceuticals; Biotechnology; See more in Biomedtracker. Latest on Mavalon Therapeutics Ltd. Already A Biomedtracker Subscriber? …See details»
Mavalon Therapeutics - Crunchbase
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases. Excision is developing CRISPR-based therapies to …See details»